Slide 1: 9M 2018 Revenues Conference Call
me cegedim 9M 2018 Revenues Conference Call October 25*, 2018
Slide 2: Caution Concerning Forward-Looking Statements
Caution Concerning Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but tha
Slide 3: IFRS Rules
IFRS Rules 3 IFRS 5: Owing to the disposal of the Group’s Cegelease and Eurofarmat businesses, announced in 2017 and completed on February 28, 2018, the consolidated 2017 and 2018 financial statements are presented according to IFRS 5, “Non-current assets held for sale and discontinued”. See the ann
Slide 4: Q3 and 9M 2018 Revenue
4 Q3 and 9M 2018 Revenue Revenue Revenue growth continues 4
Slide 5: Q3 2018 Revenue Growth
Q3 2018 Revenue Growth 5 5 © cegedim 2018
Slide 6: 9M 2018 Revenue Growth
9M 2018 Revenue Growth 6 © cegedim 2018
Slide 7: Cegedim BPO Revenue
Cegedim BPO Revenue Revenue 9M - 2018 Chart legend © cegedim 2018
Slide 8: Headcount
Stee §=Headcount Revenue 9M - 2018 aan . +4, (+40) 3,404 Z y y, Z L fa JUN. 2015 Dec. 2016 Dec. 2007 JUN. 2018 Sep. 2018 © cegedim 2018
Slide 9: Health Insurance, HR & e-services Division
Health Insurance, HR & e-services Division 9 The businesses that made the strongest contributions to growth over the first nine months were Cegedim SRH (HR management solutions), sales statistics for pharmaceutical products, Cegedim e-business (digitalization and data exchange), and third-party paym
Slide 10: Healthcare Professionals Division
Healthcare Professionals Division 10 Over the first nine months of 2018, division performance was hampered by the doctor computerization businesses in the US and the UK – ahead of the release of new versions, whose impact will not be felt until 2019 – and by the computerization of pharmacists in Fra
Slide 11: Making a Meaningful Investment in Telemedicine
Making a Meaningful Investment in Telemedicine 11 In response to regulatory changes enacted September 15, 2018, in the field of telemedicine, and in order to position itself as a major telemedicine player in France, the Group has decided to make a meaningful investment in its appointment scheduling
Slide 12: New Debt Structure
New Debt Structure 12 12 © cegedim 2018
Slide 13: FY 2018 Cegedim Outlook
13 FY 2018 Cegedim Outlook Finance as of October 25, 2018
Slide 14: Outlook: Cautiously Optimistic for 2018
Outlook: Cautiously Optimistic for 2018 14 • In order to position itself as a major telemedicine player in France, the Group has decided to make a meaningful investment in its appointment scheduling and remote consultation platform, Docavenue. • The Group expects for 2018: 14 These projections are p
Slide 15: Potential Impact of Brexit
Potential Impact of Brexit 15 • Cegedim operates in the UK in local currency, as it does in all the countries where it operates • No major European health program is at work in the UK 15 © cegedim 2018
Slide 16: 2018 Financial Calendar
2018 Financial Calendar 16 17 © cegedim 2018
Slide 17: 9M 2018 Revenue Annexes
17 9M 2018 Revenue Annexes as of October 25, 2018 14
Slide 18: Application of IFRS 5
Application of IFRS 5 18 On December 14, 2017, Cegedim announced that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. The deal was finalized on February 28, 2018. As a result, the consolidated 2017 and 2018 financial statements are presented according to
Slide 19: Follow us
Follow us 19 WEB SITE www.cegedim.com/finance IR APP WEBCAST CEGEDIM IR SOCIAL NETWORK 18 @cegedimgroup © cegedim 2018
Slide 20: Jan Eryk Umiastowski
20 Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 - Mob: 00 33 6 73 25 96 34 Design: Group Communications Department